Anna‐Karin Hamberg

542 total citations
14 papers, 407 citations indexed

About

Anna‐Karin Hamberg is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Anna‐Karin Hamberg has authored 14 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 8 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Anna‐Karin Hamberg's work include Pharmacogenetics and Drug Metabolism (10 papers), Hormonal Regulation and Hypertension (8 papers) and Blood Coagulation and Thrombosis Mechanisms (2 papers). Anna‐Karin Hamberg is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Hormonal Regulation and Hypertension (8 papers) and Blood Coagulation and Thrombosis Mechanisms (2 papers). Anna‐Karin Hamberg collaborates with scholars based in Sweden, United Kingdom and Russia. Anna‐Karin Hamberg's co-authors include Mia Wadelius, E. Niclas Jonsson, Roberto Padrini, Vittorio Pengo, M.G. Scordo, M-L Dahl, Farhad Kamali, M L Dahl, Peter Avery and Anders Rane and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, British Journal of Clinical Pharmacology and European Journal of Clinical Pharmacology.

In The Last Decade

Anna‐Karin Hamberg

13 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna‐Karin Hamberg Sweden 9 297 116 97 66 54 14 407
Benjamin D. Horne United States 5 314 1.1× 117 1.0× 104 1.1× 44 0.7× 63 1.2× 5 398
Shinichi Kijima Japan 6 229 0.8× 106 0.9× 61 0.6× 46 0.7× 28 0.5× 10 399
Jason Hubbard United States 2 333 1.1× 143 1.2× 73 0.8× 32 0.5× 43 0.8× 3 392
Kristen K. Reynolds United States 10 277 0.9× 97 0.8× 44 0.5× 36 0.5× 55 1.0× 15 363
Toby Nicholson United Kingdom 2 394 1.3× 83 0.7× 198 2.0× 65 1.0× 91 1.7× 4 606
Susan K. Gatchel United States 8 360 1.2× 154 1.3× 181 1.9× 55 0.8× 108 2.0× 10 539
Vasudev Kumanduri United Kingdom 3 373 1.3× 127 1.1× 83 0.9× 42 0.6× 30 0.6× 3 516
MT Lee Taiwan 4 319 1.1× 57 0.5× 75 0.8× 37 0.6× 52 1.0× 6 461
J. L. Anderson United States 2 372 1.3× 162 1.4× 146 1.5× 53 0.8× 38 0.7× 4 606
Katarzyna Drozda United States 11 337 1.1× 65 0.6× 47 0.5× 51 0.8× 37 0.7× 16 440

Countries citing papers authored by Anna‐Karin Hamberg

Since Specialization
Citations

This map shows the geographic impact of Anna‐Karin Hamberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna‐Karin Hamberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna‐Karin Hamberg more than expected).

Fields of papers citing papers by Anna‐Karin Hamberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna‐Karin Hamberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna‐Karin Hamberg. The network helps show where Anna‐Karin Hamberg may publish in the future.

Co-authorship network of co-authors of Anna‐Karin Hamberg

This figure shows the co-authorship network connecting the top 25 collaborators of Anna‐Karin Hamberg. A scholar is included among the top collaborators of Anna‐Karin Hamberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna‐Karin Hamberg. Anna‐Karin Hamberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Larsson, Anders, et al.. (2025). New Monitoring Recommendations for Digoxin During the Last Decade Are Associated With Decreased Serum Digoxin Concentrations in Patient Samples. Basic & Clinical Pharmacology & Toxicology. 137(2). e70083–e70083.
2.
Hamberg, Anna‐Karin, et al.. (2024). Model-informed precision dosing of vancomycin in clinical practice: an intervention development study. International Journal of Clinical Pharmacy. 47(1). 178–186. 2 indexed citations
3.
Bouazza, Naïm, Aristides Dokoumetzidis, Catherijne A. J. Knibbe, et al.. (2022). General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children. British Journal of Clinical Pharmacology. 88(12). 4985–4996. 2 indexed citations
4.
Hallberg, Pär, Mia Wadelius, Anna‐Karin Hamberg, et al.. (2022). Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events. Frontiers in Genetics. 13. 982955–982955. 9 indexed citations
5.
Takeuchi, Masanobu, Tohru Kobayashi, Tina Biss, et al.. (2019). CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. The Pharmacogenomics Journal. 20(2). 306–319. 12 indexed citations
6.
Hamberg, Anna‐Karin, et al.. (2015). A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. BMC Medical Informatics and Decision Making. 15(1). 7–7. 52 indexed citations
7.
Hamberg, Anna‐Karin & Mia Wadelius. (2014). Pharmacogenetics-Based Warfarin Dosing in Children. Pharmacogenomics. 15(3). 361–374. 9 indexed citations
8.
Hamberg, Anna‐Karin, Lena E. Friberg, Katarina Hanséus, et al.. (2013). Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms. European Journal of Clinical Pharmacology. 69(6). 1275–1283. 35 indexed citations
9.
Hamberg, Anna‐Karin, Mia Wadelius, Lena E. Friberg, et al.. (2013). Characterizing variability in warfarin dose requirements in children using modelling and simulation. British Journal of Clinical Pharmacology. 78(1). 158–169. 16 indexed citations
10.
Hamberg, Anna‐Karin. (2013). Pharmacometric Models for Individualisation of Warfarin in Adults and Children. KTH Publication Database DiVA (KTH Royal Institute of Technology). 3 indexed citations
11.
Avery, Peter, Andrea Jorgensen, Anna‐Karin Hamberg, et al.. (2011). A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy. Clinical Pharmacology & Therapeutics. 90(5). 701–706. 62 indexed citations
12.
Hamberg, Anna‐Karin, Mia Wadelius, Jonatan D. Lindh, et al.. (2010). A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age. Clinical Pharmacology & Therapeutics. 87(6). 727–734. 81 indexed citations
13.
Hamberg, Anna‐Karin, M-L Dahl, M.G. Scordo, et al.. (2007). A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy. Clinical Pharmacology & Therapeutics. 81(4). 529–538. 116 indexed citations
14.
Gisslén, Magnus, Jan Albert, Anders Blaxhult, et al.. (2005). Antiretroviral treatment of HIV infection: Swedish recommendations 2005. Scandinavian Journal of Infectious Diseases. 38(2). 86–103. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026